Chondrosarcoma is the third most common primary bone cancer, requiring surgical resection. However, differentiation of low-grade chondrosarcoma (grade 1) from enchondroma that is benign and only requires regular follow-up is one of the most frequent diagnostic dilemmas facing orthopedic oncologists in clinical management.
Abstract:
Chondrosarcoma is the third most common primary bone cancer, requiring surgical resection. However, differentiation of low-grade chondrosarcoma (grade 1) from enchondroma that is benign and only requires regular follow-up is one of the most frequent diagnostic dilemmas facing orthopedic oncologists in clinical management.
Although multiple techniques are applied to make the distinction, immunohistochemistry is an important ancillary technique, especially when a histopathological stain of specimen must be obtained in order to guarantee an accurate confirmation. Currently, no adequate immunohistochemical diagnostic protein biomarkers are available to distinguish low-grade chondrosarcoma from enchondroma. To discover novel protein biomarker candidates, a liquid chromatography-tandem mass spectrometry approach was applied to directly compare formalin-fixed, paraffin-embedded low-grade chondrosarcoma with enchondroma tissue samples. The proteomics analysis revealed 17 protein biomarker candidates. A principle was developed to prioritize the candidates using category and ranking. An algorithm, prioritization index of biomarker candidates for immunohistochemistry on tissue specimens (PIBIT), was developed to rank the candidates inside each category. Using the proteomics data and bioinformatics results, the PIBIT revealed periostin as a top candidate. Immunohistochemical staining of periostin in 23 low-grade chondrosarcoma and 31 enchondroma tissue specimens disclosed the specificity 87% and the sensitivity 70%.
Introduction
Chondrosarcoma is the third most common primary bone cancer [1, 2] . Based on cellularity, nuclear atypia, and pleomorphism, chondrosarcoma is histologically classified into three grades [3] , including low-grade (grade 1), intermediate grade (grade 2), and high-grade (grade 3) [4] . Wide surgical resection is the most common treatment choice for chondrosarcoma [2] . Clinically, it is crucial to distinguish low-grade chondrosarcoma from its benign counterpart enchondroma, because enchondroma only requires regular follow-up [5] .
Histologically, distinction of between a low-grade chondrosarcoma from a benign enchondroma relying solely on morphological features is difficult and even impossible in many cases for skilled pathologists because of their similar cytology, cellularity, and cartilaginous matrix [4, [6] [7] [8] . Therefore, correlative interpretation of histopathological features, x-ray imaging, computerized tomography, magnetic resonance imaging, clinical examination, and epidemiological information is currently used for making this distinction [5, 9] . Most often, however, a histopathological stain of specimen must be obtained in order to guarantee an accurate confirmation [5] . Therefore, immunohistochemistry is chosen to distinguish a low-grade chondrosarcoma from a benign enchondroma, because it has been proven to be one of the most important ancillary techniques.
Currently, numerous proteins have been immunohistochemically tested to distinguish low-grade chondrosarcoma from enchondroma. However, many of them were carried out on a small number of cases (< 10). Among the proteins tested on ≥ 10 cases, only 12 proteins, ADAM28, CCND1, FERMT2, FOS, ILK, JUN, JUNB, MAPK3, MAPK9, PARVB, PTH1R, and RUNX2 [10] [11] [12] [13] [14] , possess both sensitivity and specificity ≥ 50%.
Only 3 of the 12 proteins, FERMT2, FOS, and MAPK3, have both sensitivity and specificity ≥ 70%. It is unlikely for a biomarker to achieve 100% sensitivity and 100%
specificity. An ideal biomarker needs to have at least 90% sensitivity and 90% or more specificity [15] . Obviously, there are not enough promising candidates in the validation at a larger scale to distinguish low-grade chondrosarcoma from enchondroma.
Moreover, the majority of the tested proteins were simply chosen because either they were reported to involve signaling pathways in other tumors [13] or they play an important role in cell motility, growth, survival, and ultimately carcinogenesis [12] . They were not chosen from the direct comparison of low-grade chondrosarcoma with enchondroma.
To discover more meaningful protein candidates to meet the 90/90 standard, a global and high-throughput approach should be applied to directly compare low-grade chondrosarcoma with enchondroma. At present, genomics and proteomics have been used only in three and two publications to discover biomarker candidates for the differentiation, respectively [14, [16] [17] [18] [19] . The only applied proteomic technique is twodimensional electrophoresis that has multiple limitations in proteome analysis [20] . Not surprisingly, just a few biomarker candidates have been discovered so far. On the contrary, a shotgun proteomics approach provides better profiling of proteins because of its sensitivity and high-throughput capability [21] . Therefore, a liquid chromatographytandem mass spectrometry (LC-MS/MS) approach should be pursued for the biomarker discovery.
The goals of the present study are to discover and validate protein biomarker candidates for immunohistochemical diagnosis to distinguish low-grade chondrosarcoma from enchondroma. In this study, formalin-fixed paraffin-embedded (FFPE) tissue samples of low-grade chondrosarcoma and enchondroma were analyzed using a quantitative LC-MS/MS approach. The FFPE samples were chosen because fresh-frozen tissues were not available. One of the discovered protein biomarker candidates was validated with immunohistochemistry. The results indicated that the entire workflow from discovery to validation performed remarkably well, significantly expanding the number of meaningful biomarker candidates reported in previous studies.
Also, the results provided a very promising candidate for further validation at an even larger scale.
Materials and methods

Tissue blocks
This study was approved by the Indiana University Institutional Review Board (IRB # 1403932283). Two sets of FFPE tissue blocks of both low-grade chondrosarcoma and enchondroma were obtained from the Indiana University Health Pathology Laboratory. 
Label-free analysis
Protein extraction from the FFPE samples
Protein extraction from the FFPE samples was performed according to an integrated procedure including deparaffinization, rehydration, cross-link reversion, and protein extraction [22] . Briefly, after an FFPE tissue block was cut into slices (5x2.5x1 mm, lengthxwidthxheight), visible paraffin was removed with a forceps. The slices were placed in a 2.0 mL collection tube and ten volumes (500 µL for 50 mg of tissue slices) of 100 mM NH4HCO3 at pH 8.0 were added to the tube. The sample was incubated at 99 °C for 30 min at 900 rpm on an Eppendorf Thermomixer to get the First Extraction. The tissue slices were homogenized, generating a milk-like solution. The solution was incubated at 99 °C for 60 min at 900 rpm on the Eppendorf Thermomixer to obtain the Second Extraction. The Third Extraction was carried out with incubation at 99 °C for 60 min at 900 rpm. The three extractions were pooled and then stored at -80 °C until analysis. Protein concentration was determined by the Bradford Protein Assay using Bio-Rad protein assay dye reagent concentrate [23] .
Protein reduction, alkylation, and digestion for LC-MS/MS
Protein reduction, alkylation, and digestion were carried out using a method previously published by the author [24] . Briefly, a 100 µg aliquot of protein sample was placed in a 2 mL tube and dried by SpeedVac. 
LC-MS/MS analysis
The digested samples were analyzed using a Thermo Scientific Orbitrap Velos Pro hybrid ion trap-Orbitrap mass spectrometer coupled with a Surveyor autosampler and MS HPLC system (Thermo Scientific). Tryptic peptides were injected onto a C18 
Protein identification and quantification
The acquired data were searched against the UniProt protein sequence database of HUMAN (released on 02/19/2014) using X!Tandem algorithms in the Trans-Proteomic Pipeline (TPP, v. 4.6.3) (http://tools.proteomecenter.org/software.php). General parameters were set to: parent monoisotopic mass error set as 10 ppm, cleavage semi set as yes, missed cleavage sites set at 2, and static modification set as + 44.026215
Da on Cysteine. The searched peptides and proteins were validated by PeptideProphet [25] and ProteinProphet [26] in TPP. Only proteins and peptides with protein probability ≥ 0.9000 and peptide probability ≥ 0.8000 were reported. Protein quantification was performed using a label-free quantification software package, IdentiQuantXL TM [27] .
Student's t-test was used for the statistical analysis.
Bioinformatics analysis
In order to assign their subcellular locations, involvement in diseases and disorders, and network connectivity, proteins in each category were individually submitted to QIAGEN's Ingenuity ® Pathway Analysis (IPA ® , QIAGEN Redwood City, ww.qiagen.com/ingenuity) in which the Ingenuity Pathways Knowledge Base is used.
Immunohistochemistry
The immunohistochemical staining was performed at Indiana University Health Pathology Laboratory according to a published method [28] The staining of periostin was scored according to percentage of positive staining in the whole section for each case (0 = no positive staining; 1 = 1%-25% positive; 2 = 26%-50% positive; 3 = 51%-100% positive) and its intensity (0 = no staining, 1 = weak, 2 = moderate, 3 = strong staining), as described previously [10, 17] . Because periostin locates in extracellular space, only extracellular matrix staining of atypical chondrocytes and/or stroma closely associated with tumor is considered a positive result.
Immunostaining in normal bone marrow spaces should be considered negative. To assess periostin's ability to distinguish low-grade chondrosarcoma from enchondroma, each stain was assigned either positive or negative for the clinical practice when the sensitivity and specificity analyses were performed using XLSTAT (Addinsoft, New York, NY. http://www.xlstat.com/en/).
Results
Patient clinical information
The clinical data of diagnosis, location, gender, and age at diagnosis of the 64 patients (38 females and 26 males; age range, 14-95 years old; mean, 49 years) are summarized in Supplemental Table 1 . The 10 patients in Set 1 ranged in age between 29 and 81 years old (mean, 49 years). Among the 23 low-grade chondrosarcoma and 31 enchondroma tissue specimens in Set 2, the patients in low-grade chondrosarcoma group ranged in age from 27 to 95 years old (mean, 59 years). The male to female ratio was 14/9. Patients in enchondroma group ranged in age from 14 to 71 years old (mean, 41 years). The male to female ratio was 9/22.
Protein identification and quantification
From the 20 injections, 489 protein groups (unique proteins) with a probability ≥ 0.9000 were identified by 2,661 peptides with a probability ≥ 0.8000. The complete list of identified proteins is available in the Supplemental Table 2 , where proteins identified with completely identical peptides are placed into a single protein group. None of decoy proteins was included in the list according to the probability cut-offs. Therefore, the false discovery rate is 0%. Among the 489 proteins, 347 proteins were identified with at least two distinct peptides. To obtain more accurate quantification, multiple filters were applied to eliminate unqualified peptides for protein quantification [27] . The complete list of quantified proteins is available in the Supplemental Table 3 , including 400 protein groups quantified by 1,834 peptides. Among them, 270 proteins were quantified with at least two distinct peptides.
Bioinformatics analysis
Besides subcellular locations, involvement in diseases and disorders proteins, and network connectivity, IPA provided important information, such as canonical pathways, upstream regulators, regulator effects, etc. To affiliate prioritization of the biomarker candidates, only the highly related results are presented in this publication. The network connectivity and subcellular location are presented in Figures 1-3 . Among the 17 proteins, 13 proteins exist in extracellular space. The involvement in diseases and disorders proteins of each protein is presented in Table 1 . Almost all were involved with cancer except APOA4 and C1QB; 7 of the 17 proteins were related with connective tissue disorders.
Immunohistochemistry
Representative immunohistochemistry staining of periostin is presented in Figure 4 at Figure 1 . Calculated with XLSTAT, the specificity was 87% with a 95% confidence interval of 70-95% and the sensitivity was 70% with a 95% confidence interval of 49-84%.
Discussion
Principle to prioritize candidate proteins
Once numerous proteins are identified and quantified in biomarker discovery phase, a challenging task is to determine which proteins should be chosen for further validation using alternative approaches. Simply by p value and/or fold change of a protein, the determination normally generates a long list of biomarker candidates. Therefore, it is a dilemma to decide which candidate has a better chance of success in validation and should be validated first since no unlimited source for validation is available. To resolve this problem, we categorize the candidates with different priorities according to couple the most critical factors and then rank the candidates inside each category based on multiple important factors.
The aim of this study was to discover diagnostic biomarker candidates for clinical immunohistochemistry. Thus, the factors considered in candidate selection should be different from other approaches, such as concentration measurement in blood using ELISA or MRM (multiple reaction monitoring). An ideal biomarker should be positively stained in low-grade chondrosarcoma tissue while negatively stained in enchondroma tissue; also, proteins commonly existing in blood are considered with lower priority than proteins not commonly present in blood.
Factors in categorizing of protein candidates
The first factor is the difference of protein identification frequency between low-grade chondrosarcoma and enchondroma tissues. Each group had five samples and each sample was injected twice. Therefore, 10 injections were analyzed for each group. If a protein was identified from every injection, its frequency is 1.0; if a protein was not identified from any injection, its frequency is 0.0. The detailed frequency of each protein is included in the Supplemental Table 2 . Twenty-six proteins with a frequency difference between low-grade chondrosarcoma and enchondroma ≥ 0.4 were considered potential biomarker candidates. Excluding protein isoforms, 17 unique proteins were considered biomarker candidates. The frequency difference was used to determine candidacy. Also, the frequency difference was used to rank proteins in each biomarker candidate category (described as below).
The second factor is whether a protein commonly existed in blood or skin. Because residual blood could be present in the tissue samples, proteins from blood rather than the tissue cells would be identified as well. Although minimizing contamination has been performed in mass spectrometry experiments, dead skin cells still are present in lab environments. Keratins from skin are very often detected in proteomics [29] . However, these proteins should not be easily excluded from the candidate list, since they are usually expressed in multiple types of tissues and these proteins may be from blood and/or the analyzed tissues. Therefore, keratins and common plasma proteins in the candidate list were labeled as Category 3, where proteins have lower priority in the candidate list for further validation. Among the 17 proteins, pigment epithelium-derived factor, apolipoprotein A-IV, alpha-1B-glycoprotein, complement factor B, and complement C1q subcomponent subunit B are commonly detected in plasma or serum [30] , Type II cytoskeletal 2 epidermal keratin is highly expressed in skin (http://www.genecards.org/cgi-bin/carddisp.pl?gene=KRT2#expression) and also highly detectable in plasma or serum [30] .
The third concern is the protein identification frequency in enchondroma tissue. As mentioned above, our goal was to discover proteins positively stained in low-grade chondrosarcoma tissues while negatively stained in enchondroma tissues. If a protein was not identified in any of the enchondroma injections, it was considered a stronger candidate than a protein identified in some of the enchondroma injections. Based on this criterion, proteins with a frequency > 0 are put into Category 2, in which proteins have low priority for further validation. Other proteins are put into Category 1, in which proteins have high priority among the entire list.
Criteria in ranking of candidate proteins inside categories
Besides the frequency difference described above, the first criterion is the consistency between frequency difference and fold change. To further validate candidates discovered by proteomics, immunohistochemistry is applied. Because these analytical approaches have different sensitivity and reproducibility, selection of greater fold change values is more likely to insure successful biomarker detection across different approaches. Fold change alone would serve well to rank the candidates when a protein is present in high abundance in one group (disease) but in low abundance or undetectable in the other group (control). When a protein has extremely low abundance in both groups, it is very often identified only in some injections of both groups or only identified in the disease group without detection in the control groups, potentially implying large fold difference between the two groups. However, the fold change is often not as large as expected or is sometimes very small due to detection limitation.
Without using alternative and targeting analyses, such as MRM or ELISA, it is not possible to determine the real concentration. Under these circumstances, it is difficult to solely use fold change to determine the priority. On the contrary, if a protein's fold difference is consistent with its frequency difference, this protein can be easily assigned with higher priority than other proteins whose fold difference are not consistent with their frequency difference. The consistency is expressed as fold change × frequency difference. Higher score indicates higher priority.
The second concern is the number of peptides used for protein identification. The more peptides used, the more confident the identification. Thus, a protein identified by multiple peptides has higher priority than a protein identified by a single peptide. Based on this criterion, proteins are further ranked inside the categories.
The third factor is protein subcellular location. From a clinical immunohistochemistry aspect, nuclear proteins are easier to achieve a better immunohistochemistry stain than cytoplasm proteins, cytoplasm proteins are easier than plasma membrane proteins, and plasma membrane proteins are easier than extracellular proteins. Therefore, the assigned priority in each category is nuclear proteins > cytoplasm proteins > plasma membrane proteins > extracellular proteins. In order to assign their cellular locations, proteins in each category were submitted to IPA. The software revealed that only AEBP1 locates in nucleus, PPIA in cytoplasm, MFI2 in plasma membrane, and all other proteins in extracellular space; KRT2 was the exception, since it was not assigned a specific location. To numerically show the importance and difference of each protein location, 10, 7, 4, 3, 1, and 0 are assigned to nucleus, cytoplasm, plasma membrane, extracellular space, and other (unknown or unassigned), respectively.
The fourth factor is the protein's relationship with targeted diseases and disorders.
Because we were looking for biomarkers for chondrosarcoma, if a protein related to connective tissue disorders or cancer, it ranked higher than other proteins. A score was assigned to each related disease or disorder for the final calculation of priority. Proteins involved in connective tissue disorders were assigned 6 points; proteins related to cancer, 3 points; and proteins involved in both disorders, 9 points. IPA analysis was applied to identify the diseases or disorders in which each protein was involved. Among the 17 proteins, 15 were involved with cancer, except APOA4 and C1QB. Seven were related to connective tissue disorders (POSTN, TGFBI, SMOC2, SERPINF1, A1BG, C1QB, and CFB).
The fifth concern is protein connectivity in a network. To find potential links among the candidate proteins, IPA analysis is applied. IPA Networks are generated based on protein connectivity with other proteins. The more connected a protein is, the more important it is and the more influence it has. Therefore, the higher priority a protein is assigned, if a protein has more interconnection with other proteins in a network. When proteins in each category were submitted to IPA, a network was generated for each category (Figures 1 -3) , indicating direct and indirect connectivity among some of the submitted proteins. The number of a protein's connections in a network were counted.
The more a protein has other proteins connected, the higher priority is assigned to the protein.
Prioritization index of biomarker candidates for immunohistochemistry on tissue specimens (PIBIT)
Multiple factors have been taken into account to rank biomarker candidates selected for immunohistochemical verification. One final score is needed to combine all the six factors. Four of these factors are numeric; i.e., frequency difference, consistency between frequency difference and fold change, number of peptides used for protein identification, and protein connectivity in a network. Protein subcellular location and the protein's involvement in targeted diseases and disorders are not, but subsequently assigned numbers for the final score calculation. Finally, the individual score of each factor is combined in a formula and a signal score is reported to rank proteins in each category.
However, their weight in the calculation should be different. The frequency difference is recorded as a fraction. To normalize the importance of each factor, the weight of frequency difference is assigned as 10. The weight of the consistency between frequency difference and fold change is given 10 as well. Therefore, the final score PIBIT was calculated using the following equation:
Where PIBIT = prioritization index of biomarker candidates for immunohistochemistry on tissue specimens, F0 = frequency difference × 10, F1 = consistency between frequency difference and fold change (fold change × frequency difference) × 10, F2 = number of peptides, F3 = subcellular location, F4 = involvement in targeted diseases and disorders, and F5 = connectivity in a network. According to the six factors, the PIBIT of each protein was calculated using the equation. All the factors and detail scores are listed in Table 1 Furthermore, this idea can be more extensively applied to other projects whose factors are not identical to the factors discussed in this study, such as sensitivity, specificity, the area under the receiver operating characteristic (ROC) curve (AUC), etc.
Basically, each factor and its weight have to be considered and then summed together.
The single final score is simple but comprehensive, facilitating the priority determination.
Selection of periostin for immunohistochemistry verification
Periostin's discovery history, structure, isoforms, expression, functions, role in carcinogenesis and tumor progression-driving, and usage as a prognostic marker and novel therapeutic target have been summarized in a recent publication [31] . Periostin, also called osteoblast-specific factor 2, is an extracellular matrix protein involved in osteology, tissue repair, oncology, cardiovascular and respiratory systems, and in various inflammatory settings [32] . Periostin plays an important role in tumor progression in various types of cancer, including breast cancer, bladder cancer, colon cancer, non-small cell lung carcinoma, head and neck cancer, ovarian cancer, pancreatic ductal adenocarcinoma, melanoma, gastric cancer, oral squamous cell carcinoma, thymoma, and neuroblastoma [31, 33] . Noticeably, the upregulation of periostin in prostate, renal, and penile cancer was usually associated with a more aggressive tumor behavior and advanced stage, while it is weakly expressed in bladder cancer tissues [31] . Generally, it is known that its overexpression in cancer indicates the most malignant phenotypes and the poorest outcomes [34] . Periostin is preferentially expressed in the periosteum that covers a large majority of bones and is responsible for changes in bone diameter and cortical thickness [33] . It is expressed at a high level during embryogenesis and bone growth [33] . Periostin activates the Akt/PKB-and FAKmediated signaling pathways, leading to increased cell survival, angiogenesis, invasion, metastasis, and epithelial-mesenchymal transition of carcinoma cells [35] . Due to its roles in tumor development, periostin has been speculated as a therapeutic and diagnostic target for cancer [36] . According to the proteomics results and the literature, periostin is a highly preferred biomarker candidate for further validation. Therefore, periostin was chosen as the first one for verification by immunohistochemistry.
Other proteins in the category 1
There are six other proteins (TGFBI, AEBP1, PCOLCE, SMOC2, MFI2, CPXM2) listed in the Category 1. TGFBI mediates cell adhesion to extracellular proteins such as collagen, fibronectin and laminins through integrin binding. It is overexpressed in several solid tumors including colon, pancreas, and kidney [37] . AEBP1 has been reported to be upregulated in stroma of mammary tumors and breast cancer cells [38] . PCOLCE stimulates procollagen processing by procollagen C-proteinases and is involved in tumor growth, neurodegenerative diseases, and angiogenesis [39] . SMOC2 enhances the angiogenic effect of basic fibroblast growth factor and vascular endothelial growth factor, mediates mitogenesis in mouse fibroblasts, interacts with vitronectin and cell surface receptors of the integrin family. Moreover, it affects the migration of keratinocytes, the process of metastasis, and pulmonary function [40] .
Melanotransferrin is expressed at low levels in normal adult tissues, but at high levels in melanoma tumors, other cancers, and foetal tissues [41] . CPXM2 is a member of the metallocarboxypeptidase gene family and identified from its homology with carboxypeptidase E [42] . It is upregulated in fetal growth restriction [43] . All six were identified with multiple peptides and involved in cancer. TGFBI and SMOC2 are related with connective tissue disorders. This information suggests that the six proteins are good candidates for further biomarker validation.
Proteins not in the category 1
There are 10 more proteins not in the Category 1 of biomarker candidates. Some have a high PIBIT score, such as decorin and pigment epithelium-derived factor. Decorin is a component of connective tissue and locates at cellular or pericellular matrix. It has become a focus in various areas of cancer research [44] . Decorin has been involved in various biological processes, such as collagen fibrillogenesis, wound healing, myogenesis, stem cell biology, and fibrosis [45] . Pigment epithelium-derived factor is a serine protease inhibitor and has been detected in multiple tissues including brain, spinal cord, liver, bone, eye, heart, lung and plasma [46] . It has been reported to be a potent angiogenic inhibitor to prevent angiogenesis and metastasis, induce tumor cell apoptosis, and prevent cancer cell growth in a range of cancers, such as osteosarcoma, chondrosarcoma, lung, breast, and prostate cancer [47] . Although these proteins are Periostin locates in extralcellular space. Therefore, the matrix staining pattern is observed. 
